Clinical Trial

To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in subjects with advanced/metastatic renal cell carcinoma, and determine the recommended dose and infusion regimen for Phase 2 trials.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-03
Trial Details
NCT Number NCT07647744
Lead Sponsor Hrain Biotechnology Co., Ltd.
Collaborators: RenJi Hospital
Conditions Renal Cell Carcinoma (RCC)
Enrollment 18 participants
Start Date 2026-06-30
Primary Completion 2029-06 (estimated)
Study Completion 2034-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-02